Seasonal Respiratory Follow-Up: Prepare the Patient, Not Just the Reminder
Plan asthma and COPD follow-up around individual risks, inhaler access, exposure changes and a usable action plan without a universal pre-winter visit.
Use tobacco cessation follow-up to understand actual tobacco use, support the person's agreed quit attempt and resolve barriers to the chosen care plan. The 5As—Ask, Advise, Assess, Assist and Arrange—can structure the conversation, but useful follow-up needs an owner, a practical next step and honest outcome recording. A lapse, a missed call or switching tobacco products should not be hidden behind a 'counselled' checkbox.
Indian OPD, dental and primary-care teams supporting adults who use cigarettes, beedis, hookah or smokeless tobacco, with appropriate clinical referral and treatment.
A question asking only 'Do you smoke?' can miss a person using gutkha or another smokeless product. Ask about tobacco products directly, using familiar local names, and preserve what the patient says rather than guessing the contents from a brand.
Record frequency, context and recent changes as reported information. A sachet, a beedi and a cigarette are not interchangeable units. Avoid converting them into a single invented exposure score.
WHO's 2024 guideline covers cessation support for adults using a range of tobacco products, including smoked and smokeless tobacco. It recommends behavioural support and addresses clinician-led treatment. This article does not supply a medicine choice or regimen.
Ask about previous attempts and what helped or made them difficult. The purpose is to identify a useful next step, not to test willpower or require the person to prove commitment before receiving support.
Keep the scope clear. Advice for children, pregnancy or other specific circumstances needs the appropriate clinical framework. Do not apply a generic adult medicine pathway simply because the person appears on the same clinic list.
Source: WHO: Clinical treatment guideline for tobacco cessation in adults, 2 July 2024
WHO's implementation annex names the 5As and describes supportive systems and team involvement. The model is a conversational structure, not five mandatory text boxes that demonstrate an intervention happened.
Brief advice should lead somewhere usable. A patient interested in quitting may need a clinician discussion, behavioural support, a practical contact arrangement or help understanding the selected treatment. A referral name without access details can leave the person unsupported.
If the person is not ready to set a quit date, explore their concerns respectfully and agree whether and how to revisit the subject. Do not fabricate readiness to make the template complete.
The original table shows information a clinic can preserve at each step. It deliberately separates the patient's choice from staff assumptions and does not reproduce a WHO form.
On a narrow screen, scroll the table horizontally to read all columns.
| Step | Useful record | Next practical question |
|---|---|---|
| Ask | Products and current pattern, attributed to the patient | What use might a smoking-only question miss? |
| Advise | Clear personalised advice actually discussed | What health concern matters to this person? |
| Assess | Interest, uncertainty, prior attempts and current preference | What kind of support would they accept now? |
| Assist | Agreed behavioural support and any clinician-selected treatment | Can the person access and understand the plan? |
| Arrange | Named follow-up owner, permitted contact and review purpose | Who will respond to difficulty or a change in the attempt? |
Source: WHO 2024 tobacco guideline: Annex 2, implementation information
Ask when and where tobacco is used: during a work break, a commute, after meals or with a particular social group. The patient and treating team can identify feasible responses to those situations instead of issuing a generic instruction to avoid every trigger.
Discuss household and workplace support with the patient's permission. A family member may be helpful, but contacting them without agreement can expose sensitive information or create pressure. Support is not surveillance.
Check access to the selected service or treatment. Travel, cost, language, stock availability and inconvenient counselling hours can interrupt an otherwise reasonable plan. Record the barrier so someone can help resolve it.
Where medicines are part of the plan, the qualified clinician determines suitability and instructions. Staff should route side effects, uncertainty or supply problems for review rather than recommend changes from a reminder script.
In a fictional spending discussion, three ₹10 sachets per day amount to ₹30 daily, or ₹900 over a stated 30-day month. This is the patient's illustrative reported pattern, not a standard cost or guaranteed saving. Costs can make the conversation concrete, but health support should not be reduced to a sales-style savings promise.
A follow-up conversation should ask what happened since the previous plan, including days without tobacco, use after a quit attempt and any switch between products. Record the account without turning a lapse into a moral judgement.
Stopping cigarettes while continuing smokeless tobacco is a change in the pattern, not evidence of stopping all tobacco. State the outcome being described so the next professional does not assume a broader result.
Ask whether the agreed support was actually available and useful. A person who could not obtain a prescribed treatment or reach counselling has a different problem from someone who tried the plan and found it difficult.
Use the review to agree the next step with the patient: further support, a revised approach, an appropriate clinical review or a later discussion. Do not restart a fixed message sequence automatically without checking the person's preference.
Contact should remain recognisable and permitted. A shared-phone message that names tobacco use can reveal information the patient did not agree to share. The channel and recipient deserve the same care as the clinical wording.
In an original fictional cohort, 20 adults agreed to a follow-up contact. Twelve are reached and eight have an unknown current outcome. Of the twelve reached, five report no tobacco use during the stated preceding seven days and seven report some use.
Five of twelve respondents is about 41.7%; five of all twenty enrolled is 25%. Both describe the same five reports with different denominators. Neither should be presented as a proven treatment success rate, and the eight unknown outcomes must remain visible.
The seven-day period is an illustrative measurement definition, not a required clinical recall schedule or a claim of long-term abstinence. Do not label self-report as biochemically verified, and do not change the reporting window between patients without making it explicit.
Measure the work as well: whether requested counselling was accessed, whether treatment questions were reviewed and how often patients received unwanted or duplicate contact. A larger message count does not necessarily mean better support.
Use results to improve access and follow-through, while leaving outcome claims proportional to the evidence. A small local series without a comparison group cannot establish how many people quit because of the reminder system.
The fictional follow-up reaches twelve of twenty adults. Five report no tobacco during the stated preceding seven days: about 41.7% of respondents or 25% of the full cohort. Eight remain unknown. These are labelled self-reports, not verified long-term quit rates or proof of programme effectiveness.
Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.
Yes. Ask about the actual products used rather than relying only on a smoking question. Keep the reported product and pattern visible for appropriate support.
No. Record the conversation and the practical support or next step actually agreed. A completed form cannot establish access, understanding or outcome.
Ask what happened, what support was available and what the person wants help with. Record the account without blame and agree an appropriate next step with the treating team.
No. It is a change in product use. Describe the actual outcome rather than label it abstinence from all tobacco.
Not without clearly defining the period, verification method, denominator and missing outcomes. A small self-reported series does not establish long-term effectiveness or causation.
Updated on . Original adult cessation-support workflow informed by WHO guidance. It does not prescribe cessation medicines, guarantee quitting or replace individual clinical assessment. No independent clinical or legal review is claimed.
Adult behavioural and treatment support across tobacco products; no universal regimen or guaranteed cessation result.
WHO guidance reproduced by NCBI names the 5As and team support; the clinic dialogue and follow-up record are original.
Plan asthma and COPD follow-up around individual risks, inhaler access, exposure changes and a usable action plan without a universal pre-winter visit.
Capture shared-phone arrangements, preferred language, permission and opt-outs without treating one contact number as authority for every patient.
Measure recall completion with fixed cohorts, task-specific evidence, clear denominators and workload checks, including a reconciled original example.
Rehearse a smoked-plus-smokeless use history, an access barrier and a follow-up after a lapse. Show a clearly labelled reporting period and preserve unreachable patients in the denominator.
Request a clinic demo